Jiangsu Hengrui Medicine Company Ltd.

Shanghai Hengrui Pharmaceutical Co., Ltd.

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Dongbing Cui

Weikang Tao

Lianshan Zhang

Piaoyang Sun

Qiyue Hu

Xiangdong Qu

Xin Ye

Shaoyu Xu

Ling L Zhang

Guoqing Cao

Yayuan Fu

Jiajian Liu

Lei Zhang

Ying Zhang

Zhen Zhang

Yali Wang

Yifang Wang

Ling Zhang

Houcong Jin

Jindong Liang

Jianyan Xu

Guiyang Jiang

Zhibin Xu

Junzhuan Qiu

Haoying Zhang

Jingping Wei

Jiping Zha

Ziyong Sun

Dong Ma

Bei Yuan

The present invention relates to a PD-L1 antibody, antigen-binding fragments, and medical application thereof. Further, the present invention relates to chimeric antibodies and humanized antibodies comprising the CDR regions of the present PD-L1 antibody, as well as a pharmaceutical composition comprising the present PD-L1 antibody and the antigen-binding fragments thereof, and their use as anti-cancer drugs. In particular, the present invention relates to a humanized PD-L1 antibody and its use in preparation of a medicament for the treatment of PD-L1 mediated disease or disorder.

PD-L1 antibody, antigen-binding fragment thereof and medical application thereof

An interleukin 15 (IL-15) protein complex is provided. The IL-15 protein complex includes soluble fusion proteins (I) and (II), wherein the fusion protein (I) is an IL-15 polypeptide or a functional fragment thereof, and the soluble fusion protein (II) is an IL-15R&#x3b1; polypeptide or a functional fragment thereof. The soluble fusion protein (I) has at least one amino acid residue mutated to a cysteine (Cys) residue, which pairs with a corresponding mutated Cys residue on the soluble fusion protein (II), or vice versa, to form one or more disulfide bonds. The IL-15 protein complex can be used for tumor therapy.

Interleukin 15 protein complex and use thereof

Interleukin 15 protein complex

The present invention provides a PCSK9 antibody, an antigen-binding fragment thereof, and a medicinal application thereof. Provided in the invention is a chimeric antibody and a humanized antibody, both comprising a CDR of the PCSK9 antibody, and a pharmaceutical composition comprising the PCSK9 antibody and an antigen-binding fragment thereof, and an application of the PCSK9 antibody as a lipid-lowering agent. The invention specifically relates to an application of a humanized PCSK9 antibody for preparing a pharmaceutical drug to treat a PCSK9-induced disease or symptom.

PCSK9 antibody, antigen-binding fragment thereof, and medical application thereof

Provided are an anti-c-Met antibody or an antigen binding fragment thereof, and an anti-c-Met antibody-cytotoxic drug conjugate, wherein the antibody or antigen binding fragment thereof is a chimeric antibody or a humanized antibody. Also provided are pharmaceutical compositions containing the humanized anti-c-Met antibody or antigen binding fragment thereof, the antibody-cytotoxic drug conjugate, or pharmaceutically acceptable salts or solvents thereof, that are used in the treatment of cancer.

Anti-c-Met antibody and anti-c-Met antibody-cytotoxic drug conjugate and pharmaceutical use thereof

Provided is a humanized antibody and chimeric antibody that specifically binds human sclerostin. The antibodies can be used for treating human bone metabolism related diseases such as osteoporosis (OP).

Anti-sclerostin antibody, antigen binding fragment and medical use thereof

Growing community of inventors

Shanghai, China

Dongbing Cui